Ads by Google

Drug Clinical Trials

Peptimmune Initiates Trial Of PI-2301 In Multiple Sclerosis Patients

Peptimmune a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis.

Health and Wellness: 

Pages